press releases
Welcome to the Addex media center. Addex is committed to providing timely and accurate information. The information contained in each press release was factually accurate on the date of publication. Addex assumes no responsibility for updating the information to reflect subsequent developments.
To sign up to receive Addex news by email click here.
2008
24 April 2008
Addex Starts ADX10059 Phase I Formulation Selection Study read more
18 April 2008
Laurent Massuyeau Appointed Head of Business Development read more
18 April 2008
Ray Hill Elected to Board, All Board Proposals Passed at 2008 AGM read more
27 March 2008
Addex Pharmaceuticals R&D Day on April 24 read more
26 March 2008
Mark Epping-Jordan, Chief Scientific Officer, Resigns read more
17 March 2008
Disclosure of Shareholdings in accordance with Stock Market Rule read more
26 February 2008
Addex Full Year 2007 Financial Results read more
»webcast & supporting documents«
25 February 2008
Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc. read more
3 January 2008
Addex and Merck & Co. Collaborate to Develop Drugs for Schizophrenia read more
»webcast & supporting documents«
3 January 2008
Addex Announces ADX10059 Phase IIa Acute Anxiety Data read more
»webcast & supporting documents«
2007
3 December 2007
Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson's Disease read more
»webcast & supporting documents«
29 November 2007
Addex Confirms Extension of Major Shareholder Lock-up read more
29 October 2007
Addex Presents ADX10059 GERD Data at Conference read more
1 October 2007
ADX10061 Smoking Cessation Data read more
»webcast & supporting documents«
17 August 2007
Addex Pharmaceuticals appoints Head of ADME/PK read more
25 July 2007
Addex Pharmaceuticals first half 2007 financial results read more
»webcast & supporting documents«
18 July 2007
Addex First Half 2007 financial results invitation read more
21 May 2007
Addex Prices IPO shares at CHF73, raises CHF137 million read more
16 May 2007
Addex appoints Head of IR and Communications read more
9 May 2007
Addex launches IPO on SWX Swiss Exchange read more
23 April 2007
Addex Pharmaceuticals plans IPO on SWX Swiss Exchange read more
20 April 2007
Addex Reports positive results in Phase IIa clinical trial with ADX10059 in migraine read more
17 April 2007
Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in gastro-esophageal reflux disease read more
10 April 2007
Addex initiates Phase I trials on ADX48621, a novel compound for treatment of depression, anxiety disorder and pain read more
24 January 2007
Addex starts Phase IIa proof of concept study on ADX10061 for smoking cessation read more
2006
19 December 2006
Addex begins Phase IIa proof of concept study on ADX10059 for treatment of acute anxiety read more
19 September 2006
Addex Pharmaceuticals raises CHF40 million - SR One and Roche Venture funds invest in series C private financing read more
30 August 2006
Addex Pharmaceuticals initiates Phase II clinical trials with ADX10059 read more
2005
22 September 2005
Addex Pharmaceuticals initiates Phase I trials with ADX10059, a novel compound intended for anxiety and migraine read more
26 January 2005
Addex Pharmaceuticals named by tornado insider among Europe's top 100 private tech companies - Best Performing Companies of 2004 read more
17 January 2005
Addex Pharmaceuticals enters into collaboration with Ortho-McNeil Pharmaceutical to develop novel treatments for anxiety, depression, schizophrenia and alzheimer's disease read more
2004
11 novembre 2004
Addex Pharmaceuticals lauréate du Prix de la Jeune Industrie de Genève read more
17 May 2004
Addex Pharmaceuticals completes largest ever European biotech series B fund raising read more
2003
10 December 2003
Addex Pharmaceuticals signs three year clinical development partnership with Fulcrum Pharma plc read more
2002
18 December 2002
CeNeS announces Phase II drug deal with Addex Pharmaceuticals read more
11 July 2002
Addex Pharmaceuticals attracts venture funding from leading European VC firms read more